• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫治疗时代放疗后胸段肿瘤的假性进展:病例系列

Pseudoprogression of thoracic tumor after radiotherapy in the era of immunotherapy: a case series.

作者信息

Xiang Yongbo, Tang Wei, Wang Jianyang, Wang Zhijie, Bi Nan

机构信息

Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Center for National Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

Front Oncol. 2023 Jul 28;13:1021253. doi: 10.3389/fonc.2023.1021253. eCollection 2023.

DOI:10.3389/fonc.2023.1021253
PMID:37576884
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10419187/
Abstract

Pseudoprogression is rarely mentioned after radiotherapy except for central nervous system tumors. With the widespread of immunotherapy, the incidence of pseudoprogression of thoracic tumor after radiotherapy is increasing. This study summarized the clinical features of pseudoprogression in 4 patients who had underwent thoracic radiotherapy after and/or followed by immunotherapy. All of them had received chemotherapy and immunotherapy before thoracic radiotherapy. After radiotherapy, pseudoprogression occurred within 3 months after initiation of immune consolidation/rechallenge therapy. At least a 20% increase in the sum of the longest diameter of target lesions were measured on their chest image. During this period, patients' ECOG PS scores remained stable, specific serum tumor markers did not increase significantly. Treatment strategies did not change after pseudoprogression. The causes of radiographic pseudoprogression in this case series may be attributed to disturbances such as pneumonitis, atelectasis, mucus blockages and infection. In the era of immunotherapy, pseudoprogression of thoracic tumors after chest radiotherapy might become a common phenomenon. It is important for us to identify pseudoprogression based on patient's general status, radiological changes, and laboratory tests.

摘要

除中枢神经系统肿瘤外,放疗后很少提及假性进展。随着免疫疗法的广泛应用,放疗后胸段肿瘤假性进展的发生率正在增加。本研究总结了4例接受胸段放疗后和/或放疗后接受免疫治疗的患者假性进展的临床特征。他们均在胸段放疗前接受过化疗和免疫治疗。放疗后,在免疫巩固/再激发治疗开始后3个月内出现假性进展。胸部影像显示靶病灶最长径总和至少增加20%。在此期间,患者的东部肿瘤协作组(ECOG)体力状况评分保持稳定,特异性血清肿瘤标志物未显著升高。假性进展后治疗策略未改变。本病例系列中影像学假性进展的原因可能归因于肺炎、肺不张、黏液阻塞和感染等干扰因素。在免疫治疗时代,胸段放疗后胸段肿瘤的假性进展可能会成为一种常见现象。基于患者的一般状况、影像学变化和实验室检查来识别假性进展对我们来说很重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fa6/10419187/ce3e45991480/fonc-13-1021253-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fa6/10419187/70ab3bfe8aa6/fonc-13-1021253-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fa6/10419187/ce3e45991480/fonc-13-1021253-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fa6/10419187/70ab3bfe8aa6/fonc-13-1021253-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fa6/10419187/ce3e45991480/fonc-13-1021253-g002.jpg

相似文献

1
Pseudoprogression of thoracic tumor after radiotherapy in the era of immunotherapy: a case series.免疫治疗时代放疗后胸段肿瘤的假性进展:病例系列
Front Oncol. 2023 Jul 28;13:1021253. doi: 10.3389/fonc.2023.1021253. eCollection 2023.
2
Case Report: Pseudoprogression With Nivolumab and Bevacizumab Followed by Recurrent Immune-Related Pneumonitis in Urothelial Carcinoma With Lung Metastasis.病例报告:纳武单抗和贝伐单抗治疗后出现假性进展,随后肺转移尿路上皮癌发生复发性免疫相关性肺炎。
Front Oncol. 2021 Feb 2;10:611810. doi: 10.3389/fonc.2020.611810. eCollection 2020.
3
Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review.微卫星高度不稳定型结直肠癌在接受T细胞介导的联合免疫治疗期间出现假性进展:一例报告及文献综述
Oncotarget. 2017 Jun 3;8(34):57889-57897. doi: 10.18632/oncotarget.18361. eCollection 2017 Aug 22.
4
The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy.免疫治疗后肿瘤假性进展的潜在机制、识别及临床意义
Cancer Biol Med. 2019 Nov;16(4):655-670. doi: 10.20892/j.issn.2095-3941.2019.0144.
5
Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy.评估免疫治疗治疗的结直肠和胰腺肿瘤的假性进展。
J Immunother. 2018 Jul/Aug;41(6):284-291. doi: 10.1097/CJI.0000000000000222.
6
Tumor pseudoprogression during nivolumab immunotherapy for lung cancer.纳武单抗免疫治疗肺癌期间的肿瘤假性进展
Radiologia (Engl Ed). 2019 Nov-Dec;61(6):498-505. doi: 10.1016/j.rx.2019.05.004. Epub 2019 Jul 9.
7
Pseudoprogression during successful rechallenge of immune checkpoint inhibitor in a NSCLC patient.免疫检查点抑制剂治疗成功后复发性非小细胞肺癌的假性进展。
Adv Respir Med. 2021;89(3):316-319. doi: 10.5603/ARM.a2021.0016.
8
DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy.DCE-MRI 灌注预测免疫治疗后转移性黑色素瘤的假性进展。
J Neurooncol. 2020 Jan;146(2):339-346. doi: 10.1007/s11060-019-03379-6. Epub 2019 Dec 24.
9
Cerebral blood flow changes after radiation therapy identifies pseudoprogression in diffuse intrinsic pontine gliomas.放疗后脑血流变化可识别弥漫性内在脑桥胶质瘤的假性进展。
Neuro Oncol. 2018 Jun 18;20(7):994-1002. doi: 10.1093/neuonc/nox227.
10
Tumor pseudoprogression of spinal metastasis after radiosurgery: a novel concept and case reports.立体定向放射治疗后脊柱转移瘤的假性进展:一个新概念及病例报告
J Neurosurg Spine. 2015 May;22(5):534-9. doi: 10.3171/2014.10.SPINE14444. Epub 2015 Feb 6.

引用本文的文献

1
Cancer Immunotherapy and Medical Imaging Research Trends from 2003 to 2023: A Bibliometric Analysis.2003年至2023年癌症免疫治疗与医学成像研究趋势:文献计量分析
J Multidiscip Healthc. 2024 May 6;17:2105-2120. doi: 10.2147/JMDH.S457367. eCollection 2024.

本文引用的文献

1
Elevated tumor markers for monitoring tumor response to immunotherapy.用于监测肿瘤对免疫疗法反应的肿瘤标志物升高。
EClinicalMedicine. 2022 Apr 8;46:101381. doi: 10.1016/j.eclinm.2022.101381. eCollection 2022 Apr.
2
Pseudoprogression prediction in high grade primary CNS tumors by use of radiomics.基于影像组学预测高级别原发性中枢神经系统肿瘤的假性进展
Sci Rep. 2022 Apr 8;12(1):5915. doi: 10.1038/s41598-022-09945-9.
3
Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.胶质母细胞瘤治疗后的影像学表现:进展、假性进展、假性反应、放射性坏死
Radiol Clin North Am. 2019 Nov;57(6):1199-1216. doi: 10.1016/j.rcl.2019.07.003. Epub 2019 Aug 16.
4
Pseudoprogression after radiation therapies for low grade glioma in children and adults: A systematic review and meta-analysis.儿童和成人低级别胶质瘤放疗后假性进展:系统评价和荟萃分析。
Radiother Oncol. 2020 Jan;142:36-42. doi: 10.1016/j.radonc.2019.07.013. Epub 2019 Aug 17.
5
Pseudoprogression: an indicator for cure in combined immunotherapy?假性进展:联合免疫治疗中的治愈指标?
Immunotherapy. 2019 Sep;11(13):1087-1093. doi: 10.2217/imt-2019-0034. Epub 2019 Jul 30.
6
Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy.免疫治疗的非小细胞肺癌患者的免疫RECIST标准及症状性假性进展
Radiol Oncol. 2018 Oct 18;52(4):365-369. doi: 10.2478/raon-2018-0037.
7
Pseudoprogression of brain tumors.脑肿瘤的假性进展
J Magn Reson Imaging. 2018 May 7;48(3):571-89. doi: 10.1002/jmri.26171.
8
Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.抗程序性细胞死亡蛋白 1 抗体治疗转移性黑色素瘤患者的循环肿瘤 DNA 与假性进展的相关性。
JAMA Oncol. 2018 May 1;4(5):717-721. doi: 10.1001/jamaoncol.2017.5332.
9
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.免疫修订实体瘤反应评估标准(imRECIST):完善评估癌症免疫治疗临床获益的指南。
J Clin Oncol. 2018 Mar 20;36(9):850-858. doi: 10.1200/JCO.2017.75.1644. Epub 2018 Jan 17.
10
Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review.抗 PD-1 药物治疗晚期黑色素瘤、肺癌、肾细胞癌和其他实体瘤患者的非典型反应:系统评价。
Cancer Treat Rev. 2017 Sep;59:71-78. doi: 10.1016/j.ctrv.2017.07.002. Epub 2017 Jul 19.